Skip to main content
    S

    Sanofi ADR (SNY)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - GENERAL • NASDAQ

    $48.39
    +0.02 (+0.04%)

    Market Cap: $116.15B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Sanofi ADR (SNY) Financials: Revenue, Profit and Cash Flow

    Updated Oct 30, 2026. Financial statements from company filings, amounts in EUR.

    Sanofi ADR reported revenue of EUR 46.72B for the fiscal year ended Dec 31, 2025, up 5.5% from the year before. That year, net income was EUR 7.81B with a net margin of 16.7%, operating cash flow was EUR 12.13B and free cash flow was EUR 10.14B. The quarter ended Sep 30, 2026 had revenue of EUR 15.23B and net income of EUR 3.02B.

    Revenue and Margins

    The operating margin was 20.5% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from EUR 34.70B, a compound annual rate of 3.4%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 202546.72B+5.5%72.1%20.5%16.7%
    Dec 202444.29B+6.4%70.2%16.4%12.6%
    Dec 202341.62B+2.6%69.7%16.7%13.0%
    Dec 202240.56B+3.5%70.7%25.1%20.6%
    Dec 202139.17B+4.8%68.7%20.7%15.9%
    Dec 202037.37B-0.7%67.5%37.8%32.9%
    Dec 201937.63B+5.5%68.2%8.1%7.3%
    Dec 201835.68B-1.5%67.9%13.1%12.1%
    Dec 201736.22B+4.4%67.9%16.0%23.2%
    Dec 201634.70BN/A69.2%18.8%13.6%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, net income rose 40.5% from the year before. In the quarter ended Sep 2026, net income rose 7.9% from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue46.72B44.29B41.62B40.56B39.17B37.37B37.63B35.68B36.22B34.70B
    Cost of revenue13.05B13.21B12.63B11.88B12.26B12.16B11.98B11.44B11.61B10.70B
    Gross profit33.67B31.08B28.99B28.68B26.92B25.21B25.65B24.24B24.61B24.00B
    Research and development7.84B7.39B6.51B6.50B5.69B5.53B6.02B5.89B5.47B5.17B
    Operating income9.60B7.25B6.96B10.16B8.13B14.11B3.05B4.68B5.80B6.53B
    Net income7.81B5.56B5.40B8.37B6.22B12.29B2.75B4.31B8.42B4.71B
    EBITDA12.48B11.03B11.39B13.51B11.54B17.53B10.66B9.18B9.64B9.90B
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue15.23B12.30B11.24B12.21B13.17B10.73B10.61B7.63B14.16B11.38B9.73B12.20B
    Gross profit11.60B9.28B8.11B8.57B9.76B7.74B7.72B5.36B10.07B7.97B6.76B8.15B
    Operating income4.71B2.38B2.27B-1.04B3.62B1.47B2.23B573.00M3.63B1.59B1.24B342.00M
    Net income3.02B343.00M1.61B-801.00M2.80B3.94B1.87B499.00M2.81B1.11B1.13B-555.00M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, total debt of EUR 18.86B exceeded cash and equivalents by 11.21B.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets126.81B132.80B126.46B126.72B120.24B114.41B112.63B111.41B99.81B104.67B
    Current assets30.95B42.59B30.66B34.03B30.56B33.70B28.94B24.65B26.35B26.69B
    Cash and equivalents7.66B7.44B8.71B12.74B10.10B13.91B9.43B6.92B10.31B10.27B
    Total liabilities55.09B54.94B52.11B51.57B51.21B51.16B53.40B52.37B41.57B46.95B
    Short-term debt4.61B4.47B2.60B4.45B3.45B3.00B4.82B2.63B1.27B1.76B
    Long-term debt14.25B11.79B14.35B14.86B17.12B19.75B20.13B22.01B14.33B16.82B
    Shareholder equity71.38B77.51B74.04B74.78B68.68B63.11B59.23B59.03B58.07B57.55B
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets130.29B129.06B128.02B126.81B129.79B124.96B131.89B132.80BN/A129.75BN/A126.46B
    Total liabilities57.05B59.49B54.88B55.09B56.26B54.68B57.47B54.94B-73.00B56.76B-74.35B52.11B
    Cash and equivalents5.97B6.35B5.54B7.66B8.91B15.36B7.99B7.44B6.79B6.79B-8.71B8.71B
    Shareholder equity72.88B69.21B72.81B71.38B73.26B70.01B74.07B77.51B73.00B72.69B74.35B74.04B
    Last 12 quarters

    Cash Flow

    In the fiscal year ended Dec 2025, free cash flow was 83.6% of operating cash flow. Dividends came to 53.2% of it.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow12.13B9.08B10.26B10.53B10.52B7.42B7.71B5.55B7.38B7.84B
    Capital expenditures1.99B3.19B2.91B2.20B2.04B2.08B1.79B1.98B1.96B2.08B
    Free cash flow10.14B5.89B7.35B8.32B8.48B5.33B5.93B3.57B5.42B5.75B
    Dividends paid5.39B4.70B4.45B4.17B4.01B3.94B3.83B3.77B3.71B3.76B
    Investing cash flow-2.76B-4.41B-6.20B-2.08B-7.30B3.59B-1.21B-12.87B639.00M-2.51B
    Financing cash flow-9.26B-5.76B-8.05B-5.82B-7.06B-6.49B-4.19B3.93B-7.90B-4.10B
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow3.87B5.42B1.68B3.44B3.75B1.46B2.09BN/A3.85B1.54B88.00M6.70B
    Capital expenditures630.00M1.51B01.86B845.00M00001.95B02.11B
    Free cash flow3.24B3.90B1.68B1.59B2.90B1.46B2.09BN/A3.85B-412.89M88.00M4.59B
    Last 12 quarters

    Frequently Asked Questions About SNY

    What is Sanofi ADR's annual revenue?

    Sanofi ADR reported revenue of EUR 46.72B for the fiscal year ended Dec 31, 2025.

    How fast is Sanofi ADR's revenue growing?

    Revenue was up 5.5% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 4.8%.

    Is Sanofi ADR profitable?

    Yes. Sanofi ADR reported net income of EUR 7.81B for the fiscal year ended Dec 31, 2025, with a net margin of 16.7%.

    How much free cash flow does SNY generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of EUR 12.13B minus capital expenditures of EUR 1.99B produced free cash flow of EUR 10.14B.

    How much debt does Sanofi ADR have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of EUR 14.25B, short-term debt of EUR 4.61B and cash and equivalents of EUR 7.66B.